CX3CL1 and metabolic syndrome: Insulin resistance–metabolic syndrome patients have been reported to benefit from strategies concerning stimulation of VSMC survival and reduction in FKN/CX3CR1 signaling to promote plaque stability through an IRS2-dependent signaling [34].